Recent Finacing
Recent Raise
ARMGO Pharma develops ARM210, an oral Rycal that repairs leaky ryanodine receptors to restore Ca2+ homeostasis, in Phase 1b and preparing Phase 2 trials for CPVT and RyR myopathies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at ARMGO Pharma.
